Pioglitazone-Induced Acute Rhabdomyolysis
- Raoudha Slim, MD1,
- Chaker Ben Salem, MD2,
- Michele Zamy, PHARMD1 and
- Michel Biour, MD1
- 1Pharmacovigilance Regional Center, Saint Antoine Hospital, Paris, France;
- 2Department of Clinical Pharmacology, Faculty of Medicine of Sousse, Sousse, Tunisia.
- Corresponding author: Raoudha Slim, raoudha.slim{at}gmail.com.
Pioglitazone, a peroxisome proliferator–activated receptor γ agonist, is a relatively new oral antidiabetes agent. It has been shown to decrease insulin resistance in patients with type 2 diabetes, resulting in lowered blood glucose concentrations and A1C values. It can be used alone or in combination with metformin or a sulfonylurea. The adverse effects of pioglitazone include weight gain, headache, and edema.
We report here a case of a patient who developed severe acute rhabdomyolysis after receiving pioglitazone. A 52-year-old man had a 2-year history of type 2 diabetes that was treated with gliclazide (60 mg/day). Six weeks after addition for pioglitazone (15 mg/day), the patient was admitted to hospital for 4 …
